Corgentech

Corgentech, Inc. has elected four individuals to vice president-level positions. The appointments include the promotions of Rolf O. Ehrhardt, M.D., Ph.D., to vice president, preclinical development; Melissa Morandi to vice president, quality assurance; Patricia Richards, M.D., Ph.D., to vice president, clinical research; and Jennifer Cook Williams to vice president, investor relations.

Dr. Ehrhardt joined the company in 2003 and most recently served as senior director, Inflammation in the research department. He has more than 15 years of experience in drug development and translational science. Prior to joining Corgentech, he was the founding president of BioSeek, Inc. Before that, Dr. Ehrhardt was at Protein Design Labs (now PDL BioPharma), where he led a scientific group focused on new target discovery/validation and development of immunotherapeutics.

Ms. Morandi joined the company in 2004 and most recently served as senior director of quality assurance drug and device. Prior to that, she held director positions in quality assurance and compliance at Biogen Idec. Previously she spent nine years managing several different quality departments at Genentech and supported product launches and regulatory inspections for the company’s oncology, cardiac and growth hormone products released during that timeframe. She also worked at Amgen in QA, supporting product launches, new facility preparations for GMP approval, compliance auditing and lot release for Epogen and Neupogen.

Dr. Richards joined Corgentech in December 2005 from AlgoRx Pharmaceuticals, where she led the Phase III research program for ALGRX 3268 and the clinical research program for ALGRX 4975. From 2000 to 2004, Dr. Richards served as medical director for pain development programs at Purdue Pharma. Prior to that, she was assistant professor of anesthesiology at NYU, serving as attending physician in the Pain Clinic and in the operating room, as well as working on clinical research programs for pain medications.

Ms. Williams joined the company in 2004 and most recently served as senior director of investor relations. She is responsible for managing the corporate communications and investor relations functions at the company. Prior to joining Corgentech, she was with Cell Genesys for nearly 10 years where she most recently served as director of corporate communications and investor relations. Ms. Williams is on the investor relations advisory committee to the Biotechnology Industry Organization and has served on the board of the Silicon Valley Chapter of the National Investor Relations Institute (NIRI) since 2003.